Artivion (NYSE:AORT) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Artivion (NYSE:AORT) issued its quarterly earnings results on Monday. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.02 by $0.04, Yahoo Finance reports. The business had revenue of $97.43 million during the quarter, compared to the consensus estimate of $92.30 million. Artivion had a negative net margin of 8.67% and a positive return on equity of 3.02%. During the same quarter in the prior year, the firm earned $0.02 EPS. Artivion updated its FY 2024 guidance to EPS.

Artivion Stock Up 13.2 %

AORT stock opened at $23.85 on Wednesday. Artivion has a 12-month low of $12.16 and a 12-month high of $25.51. The company has a quick ratio of 3.43, a current ratio of 4.85 and a debt-to-equity ratio of 1.10. The company has a market cap of $982.62 million, a price-to-earnings ratio of -31.80 and a beta of 1.66. The company has a 50 day moving average of $20.48 and a two-hundred day moving average of $18.14.

Analysts Set New Price Targets

AORT has been the subject of several research analyst reports. Stifel Nicolaus upped their price target on shares of Artivion from $22.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday. Needham & Company LLC upped their price target on shares of Artivion from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday.

Insiders Place Their Bets

In other Artivion news, SVP Marshall S. Stanton sold 2,183 shares of the stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $20.39, for a total value of $44,511.37. Following the completion of the sale, the senior vice president now owns 83,296 shares in the company, valued at approximately $1,698,405.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Artivion news, SVP Marshall S. Stanton sold 2,183 shares of the stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $20.39, for a total value of $44,511.37. Following the completion of the sale, the senior vice president now owns 83,296 shares in the company, valued at approximately $1,698,405.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Andrew M. Green sold 1,462 shares of the firm’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $20.00, for a total transaction of $29,240.00. Following the transaction, the vice president now owns 41,121 shares in the company, valued at approximately $822,420. The disclosure for this sale can be found here. Insiders sold a total of 149,952 shares of company stock worth $2,891,627 in the last quarter. 8.10% of the stock is currently owned by corporate insiders.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.